Supplement-Protonix treats erosive esophagitis
Supplement-Protonix treats erosive esophagitis
Wyeth-Ayerst Laboratories, a division of American Home Products in Madison, NJ, recently announced receiving Food and Drug Administration approval for Protonix (pantoprazole sodium) delayed-release tablets for the treatment of erosive esophagitis, one of the more serious forms of gastroesophageal reflux disease.
Protonix is the newest in the class of drugs known as proton pump inhibitors that are indicated for the short-term treatment in the healing and symptomatic relief of erosive esophagitis.
The drug was evaluated in more than 100 clinical trials worldwide involving more than 11,000 patients. In clinical trials, the most frequently reported side effects were headache, diarrhea, and flatulence. The FDA also is reviewing additional new drug application from Wyeth-Ayerst for an intravenous formulation of Protonix.
Left untreated, erosive esophagitis may cause stricture, hemorrhage, a precancerous condition known as Barrett's esophagus, and esophageal cancer.
For more information on Protonix, visit www.ahp.com.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.